CDEK
← All drugs Report issue

fotemustine

Small moleculeexperimental

Clinical trial activity

11 trials · 16 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
10
Phase 3
4
Phase 4
1

Earliest trial started Apr 1, 2002 (NCT01359956)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • DNACROSS-LINKING AGENT

    DNA cross-linking agent

  • DNACROSS-LINKING AGENT

    DNA cross-linking agent

Chemistry & pharmacology

Loading structure…

SMILES

CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O
Mol. weight
315.69 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • (+-)-diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate
  • (+-)-diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate
  • diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate
  • diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate
  • diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate
  • fotemustin
  • fotemustina
  • fotemustina
  • fotemustine
  • fotemustine
  • fotemustine
  • fotemustine
  • fotemustine
  • fotemustine
  • fotemustine
  • fotemustine
  • fotemustinum
  • fotemustinum
  • muphoran
  • muphoran
  • mustoforan
  • mustophorane
  • s 10036
  • s-10036
  • s-10036
  • s-10036
  • servier brand of fotemustine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05274139Phase 2Mar 2, 2017Zhengzhou University
NCT01983124Phase 2Feb 1, 2013Istituto Nazionale per lo Studio e la Cura dei Tumori, University of Genoa, Vita-Salute University of Milano. Italy
NCT02460068Phase 3Dec 1, 2012Bristol-Myers Squibb, Italian Network for Tumor Biotherapy, University of Siena
NCT01960192Phase 4Jun 1, 2012Zhengzhou University
NCT01474239Phase 2Nov 1, 2011Roche
NCT01654692Phase 2Jun 1, 2010Bristol-Myers Squibb, Italian Network for Tumor Biotherapy, University of Siena
NCT01069627Phase 2Dec 15, 2009Roche
NCT02843386Phase 3Jun 23, 2009Curie Institute, Servier, UNICANCER
NCT00110123Phase 3Jan 1, 2005European Organisation for Research and Treatment of Cancer, University of Lausanne
NCT00560118Phase 2Aug 1, 2003University of Montpellier
NCT01359956Phase 3Apr 1, 2002Fondazione Giovanni Pascale, University of Campania Luigi Vanvitelli
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (16)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bristol-Myers SquibbFor profit2022010
Italian Network for Tumor BiotherapyAcademic/Hospital2222010
RocheFor profit2212009
University of SienaAcademic/Hospital2022010
Zhengzhou UniversityAcademic/Hospital2222012
Curie InstituteAcademic/Hospital1112009
European Organisation for Research and Treatment of CancerAcademic/Hospital1112005
Fondazione Giovanni PascaleAcademic/Hospital1112002
Istituto Nazionale per lo Studio e la Cura dei TumoriAcademic/Hospital1012013
ServierFor profit1012009
UNICANCERAcademic/Hospital1012009
University of Campania Luigi VanvitelliAcademic/Hospital1012002
University of GenoaAcademic/Hospital1112013
University of LausanneAcademic/Hospital1012005
University of MontpellierAcademic/Hospital1112003
Vita-Salute University of Milano. ItalyAcademic/Hospital1012013
16 organizations
Page 1 / 1